v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses    
Research and development expenses $ 59,077 $ 44,711
Selling, general and administrative expenses 7,247 7,892
Total operating expenses 66,323 52,603
Operating loss (66,323) (52,603)
Gain from warrant liability 598 3,315
Financial investment income 5,122 3,914
Interest expense (4,619) (2,234)
Other loss, net (3,496) (1,734)
Loss before income taxes (68,718) (49,342)
Income tax expense (benefit) 95 (558)
Net loss $ (68,813) $ (48,784)

Source